Annual CFF
-$1.04 M
+$3.94 M+79.14%
31 December 2023
Summary:
Pharming Group NV annual cash flow from financing activities is currently -$1.04 million, with the most recent change of +$3.94 million (+79.14%) on 31 December 2023. During the last 3 years, it has fallen by -$61.73 million (-101.71%). PHAR annual CFF is now -101.24% below its all-time high of $84.04 million, reached on 31 December 2007.PHAR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$1.43 M
+$26.87 M+94.94%
30 September 2024
Summary:
Pharming Group NV quarterly cash flow from financing activities is currently -$1.43 million, with the most recent change of +$26.87 million (+94.94%) on 30 September 2024. Over the past year, it has dropped by -$6.67 million (-127.35%). PHAR quarterly CFF is now -101.98% below its all-time high of $72.55 million, reached on 31 December 2016.PHAR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$33.23 M
-$6.67 M-25.13%
30 September 2024
Summary:
Pharming Group NV TTM cash flow from financing activities is currently -$33.23 million, with the most recent change of -$6.67 million (-25.13%) on 30 September 2024. Over the past year, it has dropped by -$33.49 million (-12929.34%). PHAR TTM CFF is now -144.19% below its all-time high of $75.19 million, reached on 30 September 2017.PHAR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PHAR Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +79.1% | -127.3% | -10000.0% |
| 3 y3 years | -101.7% | +47.3% | -15.3% |
| 5 y5 years | +94.9% | +77.2% | +42.1% |
PHAR Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -101.7% | +96.3% | -127.3% | +94.9% | <-9999.0% | at low |
| 5 y | 5 years | -101.7% | +98.4% | -102.4% | +94.9% | -154.8% | +47.6% |
| alltime | all time | -101.2% | +98.4% | -102.0% | +95.4% | -144.2% | +47.6% |
Pharming Group NV Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.43 M(-94.9%) | -$33.23 M(+25.1%) |
| June 2024 | - | -$28.30 M(+1045.4%) | -$26.55 M(+2917.6%) |
| Mar 2024 | - | -$2.47 M(+142.3%) | -$880.00 K(-15.3%) |
| Dec 2023 | -$1.04 M(-79.1%) | -$1.02 M(-119.5%) | -$1.04 M(-501.2%) |
| Sept 2023 | - | $5.24 M(-299.3%) | $259.00 K(-103.8%) |
| June 2023 | - | -$2.63 M(-0.0%) | -$6.90 M(+46.1%) |
| Mar 2023 | - | -$2.63 M(-1046.0%) | -$4.72 M(-5.2%) |
| Dec 2022 | -$4.98 M(-82.2%) | $278.00 K(-114.5%) | -$4.98 M(-9.0%) |
| Sept 2022 | - | -$1.92 M(+325.7%) | -$5.47 M(-12.7%) |
| June 2022 | - | -$451.00 K(-84.4%) | -$6.28 M(-77.9%) |
| Mar 2022 | - | -$2.89 M(+1243.7%) | -$28.46 M(+1.8%) |
| Dec 2021 | -$27.95 M(-146.1%) | -$215.00 K(-92.1%) | -$27.95 M(-3.1%) |
| Sept 2021 | - | -$2.72 M(-88.0%) | -$28.83 M(+12.9%) |
| June 2021 | - | -$22.63 M(+850.9%) | -$25.54 M(+1334.0%) |
| Mar 2021 | - | -$2.38 M(+117.4%) | -$1.78 M(-102.9%) |
| Dec 2020 | $60.69 M(-195.6%) | -$1.09 M(-292.6%) | $60.69 M(+29.6%) |
| Sept 2020 | - | $568.60 K(-49.5%) | $46.83 M(+17.1%) |
| June 2020 | - | $1.13 M(-98.1%) | $39.98 M(+43.3%) |
| Mar 2020 | - | $60.09 M(-502.0%) | $27.90 M(-144.0%) |
| Dec 2019 | -$63.47 M(+208.9%) | -$14.95 M(+137.7%) | -$63.47 M(+10.6%) |
| Sept 2019 | - | -$6.29 M(-42.6%) | -$57.40 M(-7.3%) |
| June 2019 | - | -$10.95 M(-65.0%) | -$61.96 M(+14.8%) |
| Mar 2019 | - | -$31.29 M(+252.4%) | -$53.96 M(+162.6%) |
| Dec 2018 | -$20.55 M(+426.1%) | -$8.88 M(-18.1%) | -$20.55 M(+12.8%) |
| Sept 2018 | - | -$10.84 M(+266.9%) | -$18.22 M(+287.6%) |
| June 2018 | - | -$2.95 M(-238.8%) | -$4.70 M(+50.7%) |
| Mar 2018 | - | $2.13 M(-132.5%) | -$3.12 M(-20.1%) |
| Dec 2017 | -$3.90 M(-105.5%) | -$6.55 M(-344.6%) | -$3.90 M(-105.2%) |
| Sept 2017 | - | $2.68 M(-295.2%) | $75.19 M(+5.4%) |
| June 2017 | - | -$1.37 M(-202.3%) | $71.37 M(-1.5%) |
| Mar 2017 | - | $1.34 M(-98.1%) | $72.46 M(+2.3%) |
| Dec 2016 | $70.81 M | $72.55 M(-6454.7%) | $70.81 M(-3476.3%) |
| Sept 2016 | - | -$1.14 M(+298.0%) | -$2.10 M(-113.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2016 | - | -$286.80 K(-7.3%) | $15.86 M(-1.7%) |
| Mar 2016 | - | -$309.40 K(-13.9%) | $16.14 M(-1.9%) |
| Dec 2015 | $16.44 M(-24.9%) | -$359.40 K(-102.1%) | $16.44 M(+8.5%) |
| Sept 2015 | - | $16.81 M(<-9900.0%) | $15.16 M(-592.5%) |
| June 2015 | - | -$5800.00(+34.9%) | -$3.08 M(-119.1%) |
| Mar 2015 | - | -$4300.00(-99.7%) | $16.12 M(-26.3%) |
| Dec 2014 | $21.88 M(-24.9%) | -$1.64 M(+15.0%) | $21.88 M(-34.7%) |
| Sept 2014 | - | -$1.43 M(-107.4%) | $33.52 M(-3.7%) |
| June 2014 | - | $19.20 M(+233.5%) | $34.82 M(+127.2%) |
| Mar 2014 | - | $5.76 M(-42.4%) | $15.33 M(-47.4%) |
| Dec 2013 | $29.12 M(+90.3%) | $9.99 M(-8222.6%) | $29.12 M(+27.8%) |
| Sept 2013 | - | -$123.00 K(-58.7%) | $22.79 M(-10.9%) |
| June 2013 | - | -$297.50 K(-101.5%) | $25.58 M(+2.2%) |
| Mar 2013 | - | $19.55 M(+434.1%) | $25.03 M(+63.6%) |
| Dec 2012 | $15.30 M(-6.7%) | $3.66 M(+37.2%) | $15.30 M(+46.8%) |
| Sept 2012 | - | $2.67 M(-415.2%) | $10.43 M(-2.3%) |
| June 2012 | - | -$846.20 K(-108.6%) | $10.67 M(-12.6%) |
| Mar 2012 | - | $9.82 M(-907.4%) | $12.21 M(-25.6%) |
| Dec 2011 | $16.40 M(-4.3%) | -$1.22 M(-141.7%) | $16.40 M(+97.5%) |
| Sept 2011 | - | $2.91 M(+324.2%) | $8.31 M(-13.5%) |
| June 2011 | - | $686.90 K(-95.1%) | $9.61 M(-54.5%) |
| Mar 2011 | - | $14.02 M(-250.5%) | $21.12 M(+23.1%) |
| Dec 2010 | $17.15 M(+384.2%) | -$9.31 M(-321.1%) | $17.15 M(-26.3%) |
| Sept 2010 | - | $4.21 M(-65.5%) | $23.27 M(-8.8%) |
| June 2010 | - | $12.20 M(+21.3%) | $25.52 M(+70.4%) |
| Mar 2010 | - | $10.05 M(-415.0%) | $14.98 M(+323.1%) |
| Dec 2009 | $3.54 M(-113.5%) | -$3.19 M(-149.4%) | $3.54 M(-47.4%) |
| Sept 2009 | - | $6.47 M(+290.2%) | $6.73 M(+2413.3%) |
| June 2009 | - | $1.66 M(-219.3%) | $267.90 K(-119.3%) |
| Mar 2009 | - | -$1.39 M | -$1.39 M |
| Dec 2008 | -$26.19 M(-131.2%) | - | - |
| Dec 2007 | $84.04 M(+85.2%) | - | - |
| Dec 2006 | $45.38 M(+341.0%) | - | - |
| Dec 2005 | $10.29 M | - | - |
FAQ
- What is Pharming Group NV annual cash flow from financing activities?
- What is the all time high annual CFF for Pharming Group NV?
- What is Pharming Group NV annual CFF year-on-year change?
- What is Pharming Group NV quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Pharming Group NV?
- What is Pharming Group NV quarterly CFF year-on-year change?
- What is Pharming Group NV TTM cash flow from financing activities?
- What is the all time high TTM CFF for Pharming Group NV?
- What is Pharming Group NV TTM CFF year-on-year change?
What is Pharming Group NV annual cash flow from financing activities?
The current annual CFF of PHAR is -$1.04 M
What is the all time high annual CFF for Pharming Group NV?
Pharming Group NV all-time high annual cash flow from financing activities is $84.04 M
What is Pharming Group NV annual CFF year-on-year change?
Over the past year, PHAR annual cash flow from financing activities has changed by +$3.94 M (+79.14%)
What is Pharming Group NV quarterly cash flow from financing activities?
The current quarterly CFF of PHAR is -$1.43 M
What is the all time high quarterly CFF for Pharming Group NV?
Pharming Group NV all-time high quarterly cash flow from financing activities is $72.55 M
What is Pharming Group NV quarterly CFF year-on-year change?
Over the past year, PHAR quarterly cash flow from financing activities has changed by -$6.67 M (-127.35%)
What is Pharming Group NV TTM cash flow from financing activities?
The current TTM CFF of PHAR is -$33.23 M
What is the all time high TTM CFF for Pharming Group NV?
Pharming Group NV all-time high TTM cash flow from financing activities is $75.19 M
What is Pharming Group NV TTM CFF year-on-year change?
Over the past year, PHAR TTM cash flow from financing activities has changed by -$33.49 M (-12929.34%)